SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices surge amid reported tanker attacks and supply risks around the Strait of Hormuz, alongside concerns about Saudi and Russian energy infrastructure. Traders are split between betting on further gains from geopolitical disruption and warning that prices look extended and could retreat if diplomacy or supply relief eases those fears.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound after the recent AI-stock selloff has put QQQ in focus, but traders are divided over whether it marks a recovery or a short-lived relief rally and bull trap. Upcoming megacap earnings and lingering concerns about AI spending and debt, alongside rising oil prices, are adding to the volatility.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops warrant-expiration deadline is dominating discussion: holders are weighing whether the shares can reach the warrants exercise price before they expire, while traders debate whether they will lapse worthless or be extended. The uncertainty has fueled frustration over the recent pullback and Cohens actions, alongside bullish speculation that he could still provide a catalyst and bearish views that expiration would remove potential dilution.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO slide is being tied by traders to recurring lockup share releases and insider selling, alongside a TD Cowen rating-target cut and concerns about the AI-chip sector. The community is divided between expecting more downside amid valuation, customer-concentration, and scaling concerns, and viewing the selloff as an oversold opportunity based on Cerebras technology and potential demand.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

CIFR is drawing attention after a steep selloff that traders widely blame on its convertible-note financing and expected share dilution, alongside broader weakness in AI/data-center stocks and concerns about debt and financing costs. The reaction is sharply divided: many holders criticize management and fear further losses, while some see the decline as an oversold pullback and remain bullish on its AI infrastructure contracts.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hot inflation readings and rising-yield concerns have pressured rate-sensitive small caps, with traders highlighting IWMs breakdown below key moving averages and heavy demand for puts. The debate is whether oversold conditions and a possible rotation out of tech can support a rebound, or whether small caps face further downside as borrowing costs stay elevated.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock to Sell, citing lengthy commercialization timelines and a lack of firm customer commitments. The move has sharpened debate over execution risk and cash burn, with some traders viewing the selloff as a buying opportunity while others see limited commercial progress as a reason for caution.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp AI-infrastructure selloff and a relief bounce, with traders split on whether the rebound signals stabilization or another short-lived rally. Concerns about neocloud financing and capital spendingheightened by CoreWeaves debt worriescompete with the bullish view that Nebius is better positioned and could capture demand from struggling providers.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is being tied mainly to concerns about its heavy debt, financing costs and ability to fund AI infrastructure expansion, amid broader weakness in neocloud stocks. Bears warn of dilution or default, while bulls cite its contracted backlog, Nvidia ties and ARKs buying; the Goldman upgrades failure to sustain a rally underscores the divide.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is being linked by traders to falling Trump approval and approaching midterms, with many questioning Truth Socials engagement and the companys fundamentals. The conversation is overwhelmingly bearish, though a few traders see the decline as a potential short-term trading opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -15.39% and -31.82%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.09% and +2.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +14.48% and +3.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ProKidney (PROK) to Release Quarterly Earnings on Monday

ProKidney (NASDAQ:PROK) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-prokidney-corp-stock...

ProKidney (NASDAQ:PROK) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded ProKidney from a "strong sell" rating to a "sell" rating in a research report on Saturday...

ProKidney (NASDAQ:PROK) Stock Price Up 9% - Should You Buy?

ProKidney (NASDAQ:PROK) Trading 9% Higher - Here's What Happened...

ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of ProKidney Corp. (NASDAQ:PROK - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a...

ProKidney (NASDAQ:PROK) Sees Strong Trading Volume  - Time to Buy?

ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - What's Next...

Hennion & Walsh Asset Management Inc. Has $3.37 Million Holdings in ProKidney Corp. $PROK

Hennion & Walsh Asset Management Inc. lifted its stake in shares of ProKidney Corp. (NASDAQ:PROK - Free Report) by 63.5% in the 4th quarter, according to its most recent Form 13F filing with the...

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

ProKidney Corp - Ordinary Shares - Class A

ProKidney Stock Skyrockets On Positive Trial Data; Citi Sees 60% Chance Of Success

Equity

Neutral Sentiment

Shares of ProKidney surged more than 500% on Tuesday following upbeat results from its Phase 2 REGEN-007 study and a price target upgrade from Citi.&nbsp;The company is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease (CKD) and diabetes.Citi raised its price target to $9 from $6 and maintained a ‘Buy’ rating, saying the early data “exceeded expectations.”&nbsp;The firm increased the probability of success for the program to 60%, citing statistically significant efficacy seen in Group 1 of the trial, which may support accelerated approval in Phase 3 subject to FDA feedback.The REGEN-007 study showed that kidney function decline was reduced by 78% in group 1 after rilparencel treatment.&nbsp;Patients who received two injections approximately three months apart experienced an improvement in their annual eGFR slope from -5.8 to -1.3 mL/min/1.73 m², representing a statistically and clinically meaningful difference.However, Bank of America was more cautious, reiterating its ‘Underperform’ rating and $1 price target.&nbsp;The firm flagged the absence of a sham comparator, lack of a conference call to discuss the data, and regulatory ambiguity. It stated that the stock’s sharp rally “looks overdone,” especially given that detailed data are likely to be withheld for a future medical meeting.ProKidney reported that no serious side effects were observed in the trial, and the safety results were consistent with earlier studies.&nbsp;Rilparencel already holds RMAT status from the FDA and is also being tested in a larger Phase 3 trial called PROACT 1.&nbsp;The company noted that early signals from REGEN-007 reinforce previously observed efficacy trends in high-risk patient subgroups.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/PROK">ProKidney</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.One user anticipated strong momentum ahead, saying they were “thinking 100% gain tomorrow.”<stembedurl>https://stocktwits.com/MarketMana/message/620282357</stembedurl>Another poster struck a more cautious but optimistic tone, noting that while they’d “love for this ticker and its well-deserving product [to have] a double-digit run,” biotech stocks often see profit-taking after big moves.&nbsp;They said short sellers could enter soon but saw long-term potential, saying, “If Phase III pans out and it gets FDA approval, it could make you a millionaire.”<stembedurl>https://stocktwits.com/nomendivitiae/message/620278285</stembedurl>ProKidney’s stock has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

The treatment, rilparencel, showed a 78% improvement in kidney function decline in one dosing group, with no serious safety issues reported, supporting its ongoing evaluation in a larger Phase 3 trial.

ProKidney Corp

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

$PROK  early results are showing great promise. This is going to help so many people. I am in for the long haul.

king richard

📅 CATALYST REMINDER | $PROK 
October 23, 2026 — Phase 2 Clinical Data 
ProKidney will present pooled Phase 2 rilparencel safety and efficacy findings at ASN Kidney Week. 
More details in our hub. 
#PROK #Biotech #KidneyWeek

Feed

News

Sentiment

Earnings

Fundamentals

Info

PROK ProKidney Corp

Fundamentals

Latest PROK News